“…The differences could be attributed to the type of assays, that is, enzyme-linked immunosorbent assay (ELISA) vcrsus radioimmunoassay (RIA), immunoagglutination, nephelometric), the use of nionoclonal antibody versus polyclonal antibody or differences inherent in the populations studied. The average Mb peak in the AMI group exceeded those of the non-AM1 and control groups by a factor of [8][9], confirming previous reports (3,4,16), but appearing slightly higher than others (8,9,22,23). These differences could be due to computational factors, i.e., peak values versus the mean of consecutive samples, or the mean of abovenormal Mb levels, or, more likely, due to the type of AMI, extension of myocardial damage or its complications (24)(25)(26).…”